< Back to previous page
Researcher
Piet Herdewyn
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Bioinformatics and computational biology
Affiliations
- Medicinal Chemistry (Rega Institute) (Division)
Member
From1 Oct 1999 → Today
Projects
31 - 40 of 51
- New Heterocyclic compounds as Hydrogen Bonding Universal Bases.From1 Oct 2012 → 30 Sep 2014Funding: FWO fellowships
- Integrative Protein Science: from small molecules to complex biological systems. ( IPROS)From1 Apr 2012 → 31 Dec 2017Funding: IUAP-VII
- Synthesis of modified nucleotides for application in medicine and biotechnology.From1 Jan 2012 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- Bacterial secondary metabolites: a natural source of new antibiotics (BaSe-ics).From1 Jan 2012 → 31 Dec 2018Funding: FWO scientific research network
- Development of Artificial Genetic Systems for Therapeutic ApplicationsFrom10 Oct 2011 → 16 May 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Application of enzyme substrate analogues: from inhibitors with anti-mycobacterial properties to synthetic genetic polymersFrom1 Oct 2011 → 13 Sep 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Postdoctoral fellowship BANDE O.From1 Jan 2011 → 27 Apr 2012Funding: POD Federal Science Policy Office - General
- Synthesis of novel.From1 Nov 2010 → 31 Oct 2014Funding: SBO (Strategic basic research)
- Synthesis of novel and drug-like compound libraries for screening across a broad range of therapeutic areas.From1 Oct 2010 → 30 Sep 2018Funding: IOF - Industrial Research Fund, IWT / VLAIO - excluding impulse programmes
- Polymerases for synthetic nucleic acids.From1 Oct 2010 → 30 Sep 2014Funding: BOF - Concerted Research Project from 1994
Publications
1 - 10 of 344
- Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals(2024)
Authors: Peng Nie, Piet Herdewyn
- Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer(2024)
Authors: Piet Herdewyn
- Degraders in epigenetic therapy: PROTACs and beyond.(2024)
Authors: Piet Herdewyn
Pages: 1464 - 1499 - Synthetic approaches and application of clinically approved small-molecule drugs to treat hepatitis(2023)
Authors: Piet Herdewyn
- Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration(2023)
Authors: Peng Nie, Piet Herdewyn
- Design, synthesis, and anti-respiratory syncytial virus potential of novel 3-(1,2,3-triazol-1-yl)furoxazine-fused benzimidazole derivatives(2023)
Authors: Piet Herdewyn
- Synthesis and clinical application of small-molecule inhibitors of Janus kinase(2023)
Authors: Peng Nie, Piet Herdewyn
- Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update(2023)
Authors: Piet Herdewyn
- Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer(2023)
Authors: Peng Nie, Piet Herdewyn
- Recent advance of clinically approved small-molecule drugs for the treatment of myeloid leukemia(2023)
Authors: Peng Nie, Piet Herdewyn
Patents
1 - 10 of 10
- Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments (Inventor)
- Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments (Inventor)
- Prodrugs of nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Autoimmune and inflammatory disorder therapy (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral compounds, a process for their preparation, and their use for treating viral infections (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Purine analogues and their use as immunosuppressive agents (Inventor)